Spots Global Cancer Trial Database for Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer
Official Title: An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX™ 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer.
Study ID: NCT01073865
Conditions
Study Description
Brief Summary: The purpose of this study is to examine the efficacy and safety as well as the characteristics of the female hormone and study medications after administration in pre-menopausal women with estrogen receptor positive advanced breast cancer who were randomised in a 1:1 ratio to either of the two treatment groups; the ZD9393 3.6 mg depot group or ZD9393 10.8 mg depot group, both given in combination with tamoxifen tablets.
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Research Site, Ahmedabad, , India
Research Site, Bangalore, , India
Research Site, Bangalore, , India
Research Site, Chennai, , India
Research Site, Hubli, , India
Research Site, Hyderabad, , India
Research Site, Jaipur, , India
Research Site, Mumbai, , India
Research Site, Nagpur, , India
Research Site, New Delhi, , India
Research Site, New Delhi, , India
Research Site, Pune, , India
Research Site, Pune, , India
Research Site, Pune, , India
Research Site, Thiruvananthapuram, , India
Research Site, Amagasaki-shi, , Japan
Research Site, Chiba, , Japan
Research Site, Chuo-ku, , Japan
Research Site, Fukuoka-shi, , Japan
Research Site, Hamamatsu, , Japan
Research Site, Hiroshima-shi, , Japan
Research Site, Kagoshima-shi, , Japan
Research Site, Kamogawa-shi, , Japan
Research Site, Kitaadachi, , Japan
Research Site, Kumamoto-shi, , Japan
Research Site, Kyoto-shi, , Japan
Research Site, Mitaka-shi, , Japan
Research Site, Nagoya-shi, , Japan
Research Site, Nagoya-shi, , Japan
Research Site, Niigata-shi, , Japan
Research Site, Osaka-shi, , Japan
Research Site, Osaka, , Japan
Research Site, Sakai-shi, , Japan
Research Site, Sapporo-shi, , Japan
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Suwon-si, , Korea, Republic of
Research Site, Cebu City, , Philippines
Research Site, Iloilo City, , Philippines
Research Site, Lipa City, , Philippines
Research Site, Pasay City, , Philippines
Research Site, Quezon City, , Philippines
Research Site, Quezon City, , Philippines
Research Site, Kaohsiung, , Taiwan
Research Site, Taichung, , Taiwan
Research Site, Taichung, , Taiwan
Research Site, Taipei, , Taiwan
Research Site, Taipei, , Taiwan
Research Site, Bangkok, , Thailand
Research Site, Bangkok, , Thailand
Research Site, Bangkok, , Thailand
Research Site, Maharat Nakorn Ratchasima, , Thailand
Research Site, Songkla, , Thailand
Research Site, Ubonratchathani, , Thailand
Contact Details
Name: Justin Lindemann, PO
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
